TY - JOUR
T1 - Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines
AU - van Huijgevoort, Nadine C. M.
AU - del Chiaro, Marco
AU - Wolfgang, Christopher L.
AU - van Hooft, Jeanin E.
AU - Besselink, Marc G.
PY - 2019/11
Y1 - 2019/11
N2 - Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic neoplasms and other rare cystic lesions, all with different biological behaviours and variable risk of progression to malignancy. As more pancreatic cysts are incidentally discovered on routine cross-sectional imaging, optimal surveillance for patients with PCN is becoming an increasingly common clinical problem, highlighting the need to balance cancer prevention with the risk of (surgical) overtreatment. This Review summarizes the latest developments in the diagnosis and management of PCN, including the quality of available evidence. Also discussed are the most important differences between the PCN guidelines from the American Gastroenterological Association, the International Association of Pancreatology and the European Study Group on Cystic Tumours of the Pancreas, including diagnostic and follow-up strategies and indications for surgery. Finally, new developments in the management of patients with PCN are addressed.
AB - Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic neoplasms and other rare cystic lesions, all with different biological behaviours and variable risk of progression to malignancy. As more pancreatic cysts are incidentally discovered on routine cross-sectional imaging, optimal surveillance for patients with PCN is becoming an increasingly common clinical problem, highlighting the need to balance cancer prevention with the risk of (surgical) overtreatment. This Review summarizes the latest developments in the diagnosis and management of PCN, including the quality of available evidence. Also discussed are the most important differences between the PCN guidelines from the American Gastroenterological Association, the International Association of Pancreatology and the European Study Group on Cystic Tumours of the Pancreas, including diagnostic and follow-up strategies and indications for surgery. Finally, new developments in the management of patients with PCN are addressed.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073836181&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31527862
U2 - https://doi.org/10.1038/s41575-019-0195-x
DO - https://doi.org/10.1038/s41575-019-0195-x
M3 - Review article
C2 - 31527862
SN - 1759-5045
VL - 16
SP - 676
EP - 689
JO - Nature reviews. Gastroenterology & hepatology
JF - Nature reviews. Gastroenterology & hepatology
IS - 11
ER -